Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase 2 Trial of Exemestane plus Dasatinib vs Exemestane plus Placebo in Advanced ER-Positive Breast Cancer
2008-003183-19Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2008
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in estrogen receptor-positive breast cancer and breast cancer comparing Exemestane plus dasatinib with Exemestane plus placebo (2 arms). Primary endpoint: Progression-free survival. Started Oct 2008; status: completed.
02
Drugs
exemestanedasatinib
03
Conditions
estrogen receptor-positive breast cancerbreast cancer
Beyond the preview
Go deeper on 2008-003183-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003183-19.